Chimeric Therapeutics (ASX:CHM) has entered a trading halt on the Australian Securities Exchange as of August 17, 2026. The halt was requested by the company in anticipation of a material announcement regarding the clinical trial outcomes for its CDH17 CAR-T cell therapy program. This therapy targets advanced gastrointestinal cancers.
The suspension of trading will remain in effect until the company releases the announcement or until the market reopens on Wednesday, August 19, 2026, whichever comes first. The forthcoming data is considered potentially market-sensitive and could significantly influence the company's valuation. The company has stated it is not aware of any reason why the trading halt should not be granted.